Related Experiment Video
Updated: Feb 20, 2026
Modeling Oral-Esophageal Squamous Cell Carcinoma in 3D Organoids
Published on: December 23, 2022
CCN1 sensitizes esophageal cancer cells to TRAIL-mediated apoptosis
Tong Dang1, Cristina Modak2, Xiemei Meng1
1The Second Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, 30 Hudemulin Rd, Baotou 014030, China.
Abstract:
TRAIL is one of the best anti-cancer molecules in our body. It kills a variety of cancer cells that are resistant to conventional chemotherapy, without causing much negative impact on normal cells, because its death receptors are almost exclusively found on cancer cells. However, some cancer cells are not sensitive to TRAIL treatment, even though they express its death receptors. A second molecule is needed to help TRAIL to complete its mission. Finding such molecules now becomes a top priority in cancer research. Our study shows that CCN1 is such a molecule. CCN1 was highly expressed in the esophageal epithelium of the patients suffering from gastroesophageal reflux disease, but faded away as the situation worsened towards adenocarcinoma. Treating the tumor cells with CCN1 resulted in apoptosis, while the same treatment to the normal cells only nourished cell growth. It was TRAIL that mediated this process. Apparently, CCN1 altered the expression profile of TRAIL and its receptors in tumor cells, namely, activating TRAIL and its death receptors and shutting down its decoy receptors. CCN1 and TRAIL worked as a team to put the cancer cells to death, as elimination of either one failed apoptosis.
Insights
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) shows anti-cancer promise, but some cancers resist it. This study identifies CCN1 as a partner molecule that enhances TRAIL
Area of Science:
- Oncology
- Molecular Biology
- Cellular Signaling
Background:
- Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) selectively induces apoptosis in cancer cells.
- Some cancer cells exhibit resistance to TRAIL, necessitating combination therapies.
- CCN1's role in TRAIL-mediated apoptosis is not well understood.
Purpose of the Study:
- To investigate CCN1 as a potential sensitizer for TRAIL-resistant cancers.
- To elucidate the molecular mechanisms by which CCN1 enhances TRAIL-induced apoptosis.
- To evaluate the differential effects of CCN1 on normal versus tumor cells.
Main Methods:
- Analysis of CCN1 expression in esophageal tissues from patients with gastroesophageal reflux disease and adenocarcinoma.
- In vitro treatment of cancer and normal cells with CCN1 and/or TRAIL.
- Assessment of apoptosis induction using cell viability assays.
- Examination of TRAIL and decoy receptor expression profiles via molecular techniques.
Main Results:
- CCN1 expression inversely correlated with the progression of esophageal adenocarcinoma.
- CCN1 treatment induced apoptosis in cancer cells but promoted growth in normal cells.
- CCN1 upregulated TRAIL and its death receptors while downregulating decoy receptors in tumor cells.
- Combined CCN1 and TRAIL treatment synergistically induced cancer cell apoptosis, with single-agent treatment being less effective.
Conclusions:
- CCN1 acts as a sensitizer to TRAIL, enhancing its anti-cancer efficacy.
- CCN1's mechanism involves modulating TRAIL receptor expression, favoring apoptosis induction.
- CCN1 demonstrates potential as a therapeutic agent to overcome TRAIL resistance in cancer.
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle
01:31The Intrinsic Apoptotic Pathway